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1. MELANOMA 
 
Melanoma arises from the malignant transformation of melanocytes. Melanocytes are 
a heterogeneous group of cells that originate from the neural crest and are able to synthetize 
melanin (Cichorek M, 2013). In addition to epidermis, melanocytes are present also in hair 
and iris, determining their color, in the inner ear, nervous system, gastrointestinal tract, oral 
and genital membranes, and heart (Cichorek M, 2013). The life of melanocytes begins with 
the differentiation of some embryonic neural crest cells into melanoblasts. Then 
melanoblasts migrate, proliferate, and differentiate into mature melanocytes, which are 
characterized by a dendritic morphology and acquire special organelles called 
“melanosomes” where melanin synthesis occurs (Cichorek M, 2013). The proliferation of 
melanocytes in the skin can give rise to common, benign neoplasms called “melanocytic 
nevi”. 
 
Both genetic and environmental factors, including ultraviolet (UV) radiation, can lead 
to the appearance of melanoma. Melanoma is a very aggressive tumor, accounting for most 
skin cancer deaths and, unfortunately, its incidence is increasing. 
 
 
 
 
 
 
 
 
 
 
Figure 1: The progression of melanoma (Hodi FS, 2006). 
 
The typical development of melanoma begins with its growth along the epidermis 
(radial growth phase). When diagnosed at this stage, melanoma can be fully eradicated 
surgically. But, rapidly, the radial growth phase can progress into the vertical-growth phase, 
in which invasion of malignant cells is deeper into the dermis (Fig. 1) and, then, the 
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metastatic stage and the spreading of melanoma cells into distal organs come after (Miller 
AJ, 2006). It must be observed that not all melanomas develop following this scheme but 
some tumors can progress directly to the metastatic stage (Gray-Schopfer V, 2007). Even if, 
recently, there were significant improvements in the treatment of metastatic melanoma due 
in particular to immunotherapy, the overall survival of patients after 5-years is about 15%. 
 
1.1. CLINICAL SUB-TYPES OF MELANOMA 
 
Four main subtypes of melanoma endowing with different pathogenic behavior were 
described (Gray-Schopfer V, 2007): 
 
1. Nodular melanoma: cancer lesion typically consists of raised nodules that rapidly 
enlarge over time. Proliferation takes place through the skin in vertical growth phase manner 
(Gray-Schopfer V, 2007).  
 
2. Acral lentiginous melanoma: this form is common in people with dark skin and 
tends to be found on the palms of the hands, the soles of the feet and in the nail bed. It is not 
related to UV radiation. 50% of melanoma patients in non-Caucasian populations report this 
type of melanoma (Gray-Schopfer V, 2007). 
 
3. Lentigo maligna: this form develops due to the chronic exposure of skin, mostly in 
elderly people. Generally, this form is flat and irregular in appearance and enlarges slowly 
(Gray-Schopfer V, 2007).  
 
4. Superficial spreading melanoma: this form is the most common form and it is 
found in the edges and scattered in the epidermal region. Severe sunburn can be one cause of 
this tumor. It is the third most common cancer in USA and UK (Gray-Schopfer V, 2007). 
 
1.2. COMMON ALTERATIONS OF SIGNALLING PATHWAYS 
ASSOCIATED WITH MELANOMA 
 
Alterations of the Ras/Raf/Mek/Erk (MAP kinases) pathway are characteristically 
involved in the development and progression of melanoma. MAP kinases (MAPK) play a 
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central role in key cell functions including proliferation, gene expression, differentiation, 
survival, and apoptosis. In melanocytes, MAPK are mostly activated by stem-cell factor, 
fibroblast growth factor and hepatocyte growth factor. Hyper-activation of MAPK is found 
in 90% of melanoma patients (Gray-Schopfer V, 2007). 
 
 Mutations in NRAS gene are responsible for the activation of the MAPK pathway in 
15-30% of patients (Gray-Schopfer V, 2007). Instead, the most frequently mutated oncogene 
related to MAPK, in melanoma, is BRAF, one among the three human RAF genes. Mutated 
V600EBRAF is able to constitutively activate the MAPK pathway (Gray-Schopfer V, 2007). 
Moreover, mutated BRAF is responsible for the progression toward the metastatic stage by 
also promoting the synthesis of vascular endothelial growth factor (VEGF) (Gray-Schopfer 
V, 2007). NRAS and BRAF mutations are mutually exclusive in melanoma (Gray-Schopfer 
V, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: MAPK Pathway. 
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Another signaling pathway important for melanoma development and progression is 
the phosphoinositide-3-OH kinase (PI3K) pathway. PI3K is involved in the regulation of 
many cellular functions such as cell growth, survival, and migration (Gray-Schopfer V, 
2007). PI3K phosphorylates and activates the serine–threonine protein kinase B (AKT) 
(Fresno Vara JA, 2004). Notably, AKT is up-regulated in 60% of melanomas (Gray-
Schopfer V, 2007). PTEN is responsible for the negative regulation of PI3K/AKT pathway 
(Slipicevic A, 2005). Inactivation of PTEN enhances melanoma cell growth and survival. 
The loss of function of PTEN is observed in 5-20% of melanoma patients (Gray-Schopfer V, 
2007). Both NRAS and BRAF mutations can lead to the up-regulation of the PI3K pathway 
(Gray-Schopfer V, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: AKT Pathway. 
 
The microphthalmia-associated transcription factor (MITF) is recognized as a key 
regulator in the commitment of melanocyte lineage and acts a central part in melanoma 
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(Gray-Schopfer V, 2007). MITF is frequently less expressed in melanomas than in 
melanocytes. The increase of MITF expression in melanoma reduces the proliferation rate 
and cell tumorigenicity (Gray-Schopfer V, 2007). The expression levels of MITF seems to 
be critical for cell survival: MITF suppression leads to cell senescence while high levels 
induce differentiation; low levels are related to an invasive phenotype (Hartman ML, 2015).  
Thus, it has been hypothesized that high levels of MITF induce cell cycle block and 
differentiation whereas intermediate levels favoure proliferation  and survival (Gray-
Schopfer V, 2007; Hartman ML, 2015). It has been demonstrated that MITF can synergize 
with V600EBRAF to induce the malignant transformation of melanocytes; therefore, it is 
needed for melanoma development. Nevertheless, because MITF is addressed toward the 
degradation by MAPK phosphorylation, its expression is down-regulated at intermediate 
levels needed to maintain cell proliferation and invasiveness (Gray-Schopfer V, 2007).  
 
Other alterations of signaling pathways occurring in melanoma and involved in the 
control of cell growth and survival include the over-expression of Bcl-2, NF-kB, and AKT3, 
the up-regulation of β catenin, and the silencing of APAF-1 (Gray-Schopfer V, 2007). KIT, 
the cyclin dependent kinase inhibitor 2A (CDKN2A) and the telomerase reverse 
transcriptase (TERT) are also frequently mutated (Shain AH, 2016) 
 
Mutations concerning p53 are less common (10%) (Gray-Schopfer V, 2007). 
 
1.3. THE THERAPIES AGAINST MELANOMA 
 
Wide excision represents the definitive treatment of early stage melanomas. Instead, 
advanced melanoma is very difficult to be treated because it is known to be highly resistant 
to many common chemotherapeutic drugs. Interferon-α and interleukin-2 have been used as 
adjuvant immunotherapy for advanced melanoma but their efficacy is low. Dacarbazine is 
the reference approved chemotherapeutic drug for advanced melanoma (Gray-Schopfer V, 
2007). Currently, the most promizing tools to treat advanced melanoma seem to be targeted 
therapies and immunotherapy. Many inhibitors targeting BRAF were tested against 
melanomas carrying BRAF mutations. Sorafenib shows low efficacy against melanoma 
alone; when it is administred in addition to other chemiotherapeutic drugs, it becomes more 
efficacious (Gray-Schopfer V, 2007). Vemurafenib was approved by FDA in 2011 for 
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patients affected with melanoma having V600EBRAF mutation. Vemurafenib significantly 
improved the overall survival of these patients but the duration of its effects is limited 
because strong resistance against it occurs (Russo A, 2014). 
 
Inhibitors targeting MEK seem to be able to reduce the in vitro proliferation of 
melanomas carrying RAF mutations. However, clinical trials demonstrated that only 
trametinib can improve the patients’ survival (Russo A, 2014). 
 
Also, PI3K and mTOR inhibitors were explored against melanomas; however, their 
employment alone was demonstrated to be ineffective. They are used in combination with 
MEK inhibitors (Russo A, 2014). 
 
Immune checkpoint inhibitors are drugs targeting pathways responsible for the 
activation of the immune response toward cancer cells. In fact, melanoma cells can escape 
the attack from T cells inactivating these “immune checkpoint”. Pembrolizumab and 
nivolumab belong to this class of novel drugs: they inhibit PD-1, a protein which prevent T 
cells to attack melanoma cells. Pembrolizumab was approved by FDA in 2014: the first 
clinical trials (Keynote-001 study) demonstrated that 55% of patients with advanced 
melanoma was still alive after 2 years (Robert C, 2016). Currently, this drug seems to be the 
most promising tool against metastatic melanoma. 
 
1.4. MELANOMA AND GANGLIOSIDES 
 
Gangliosides are glycosphingolipids carrying sialic acid residues. They are present in 
the plasma membranes of all cells, particularly in the nervous system. The lipid moiety of 
gangliosides is ceramide and it is constituted by sphingosine linked to a fatty acid by an 
amide linkage (Sonnino S, 2006). Different oligosaccharide chains define the uniqueness of 
gangliosides species, their biological properties, and their ability to interact with other 
molecules (Sonnino S, 2006). Gangliosides play an important role in many events occurring 
at the plasma membrane such as signal transduction (through their ability to interact and 
modulate receptors and integrins), adhesion, and interaction with other cells. Therefore, they 
are involved in the control of cell differentiation, growth, and immune response (Furukawa 
K, 2008). Tumorigenesis leads to many modifications in ganglioside synthesis and 
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metabolism, resulting in the appearance of atypical gangliosides on cancer cell surface. 
Cancer gangliosides reveal an immune suppressive action and the ability to enhance cell 
motility, proliferation, survival, and angiogenesis (Qamsari E, 2016). 
 
Also, melanoma is characterized by a unique expression of some gangliosides, very 
different from that of healthy melanocytes. Ganglioside GD3 is considered a melanoma-
associated antigen. Its content is very low in melanocytes but it becomes abundant in 
melanoma (Furukawa K, 2008). GD3 was found also in cells characterized by high 
proliferation rate such as fetal brain tissues and mitogen-activated T lymphocytes (Furukawa 
K, 2008). GD3 has been demonstrated to increase the activation of p130Cas and paxillin, 
involved in the control of cell invasion and motility (Furukawa K, 2008). Other gangliosides 
abundant in melanoma cells are GM3, GM2, and GD2 (Furukawa K, 2008; Tringali C, 
2014). A recent work performed in the laboratory where I performed my PhD demonstrated 
that the ganglioside profile is not equal in all melanomas. Primary melanoma cell lines can 
be clustered in at least three groups: the first enclosing melanomas displaying GM3, mainly 
in the unusual form carrying N-glycolyl GM3 instead of N-acetyl GM3 and GD3; the second 
enclosing melanomas displaying GM3 at low levels, GD3, GM1, GM2, GD1a, GD2, and 
GT1b; the third enclosing melanomas displaying an intermediate ganglioside profile 
(Tringali C, 2014). The ganglioside profile of normal melanocytes is constituted by GM3 
and GD3 at very low levels, therefore, it is clear that their malignant transformation can 
activate the synthetic pathways leading to atypical gangliosides for the melanocytic lineage. 
Moreover, melanoma clustering based on ganglioside profiling showed an interesting 
correlation with the patients’ survival despite the AJCC staging and the therapies. Patients 
whose tumors were grouped in cluster 1 have the shortest survival (some months after the 
diagnosis) whereas patients whose tumors were grouped in cluster 3 were still alive after 5 
years from the diagnosis (Tringali C, 2014). Thus, gangliosides seem to be able to strongly 
affect the aggressiveness of melanoma, its progression and, then patients survival. Based on 
these results, it can be assumed that their characterization on melanomas could have an 
important diagnostic and prognostic significance. 
 
In the past, the appearance of atypical gangliosides (GD3, GM3, N-glycolyl GM3) on 
melanoma cells was also used to develop vaccines against melanomas but their efficacy was 
low. 
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2. ABERRANT GLYCOSYLATION IN CANCER AND 
SIALIDASES 
 
It has been demonstrated that modifications concerning cellular ganglioside profile 
arise from alterations of enzymes that synthethize or metabolize gangliosides, including 
sialidases (Hakomori S,  2002). Sialidases or neuraminidases (EC 3.2.1.18; exo-α-sialidase; 
N-acylneuraminosyl glycohydrolase) are glycosidases catalyzing the removal of α-
glycosidically linked sialic acid residues from carbohydrate groups of glycoproteins, 
glycolipids, and oligosaccharides (Miyagi T, 2012). Sialidases are widely distributed in 
nature, from microorganisms such as virus, bacteria, protozoa, and fungi to avian and 
mammalian species. Sialic acid is present in sialoglycoconjugates as a terminal non-reducing 
residue usually linked to galactose (α2-3 or α2-6), and to N-acetylgalactosamine or N-
acetylglucosamine (α2-6); moreover, sialic acid can be found linked to internal saccharide 
residues or it can be present in co-polymers (α2-8; α2-9). Sialic acid has been demonstrated 
to play a key role in cellular events mainly due to its hydrophilic and acidic features and to 
its ability to work as a recognition or masking site (Miyagi T, 2008). Thus, glycoconjugated 
carrying one or more sialic acid residues acquire unique characteristics and are often 
involved in cell-cell interactions, adhesion to extracellular matrix, signaling. Therefore, the 
removal of sialic acid and the catabolism of sialo-glycoconjugates catalyzed by sialidases 
strongly modulate many biological processes.  
 
Aberrant glycosylation, above all aberrant sialylation, is known to occur during 
carcinogenesis. In the 1960’s and 1970’s, the sialylation profile of cancer cells was 
particularly studied (Miyagi T, 2008). Many studies showed that an increase in the content 
of sialic acid enhanced cell adhesion whereas the bacterial sialidase action reduced 
malignancy (Miyagi T, 2008). Currently, it has been confirmed that an increase in sialylation 
is often present in glycoproteins produced by cancer cells but there is no agreement on the 
precise role played by the content of sialic acid. Instead, many studies focused their attention 
on the qualitative changes connected to sialic acid carrying glycoconjugates. Sialidases 
preferentially recognize the link α2-3 or α2-6; internal residues are quite resistant to 
hydrolysis. 
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2.1. MAMMALIAN SIALIDASES 
 
In mammals, sialidases have been proved to be involved in several cellular 
phenomena, including cell proliferation, differentiation, adhesion, cell-cell interaction, signal 
transduction, and immune response (Monti E, 2002). In mammals there are 4 genes encoding 
sialidases that differ based on their cellular localization and enzymatic characteristics. 
Sialidases can exist in the lysosome (NEU1), the cytosol (NEU2), the plasma membrane 
(NEU3), and the mitochondria/ER (NEU4) (Miyagi T, 2012). Among them, in particular, 
NEU3 plays a key role in cancer. 
 
The lysosomal sialidase, NEU1, plays a key role in the lysosomal catabolism of 
molecules containing sialic acid but it is, also involved in cancer metastasis, elastin 
disposition, lymphocytic cell activation, and exocytosis. NEU1 preferentially removes sialic 
acid residues from gangliosides, oligosaccharides, and glycoproteins. In lysosomes, NEU1 
sialidase is part of a heterotrimeric complex together with β-galactosidase and cathepsin 
(protective protein). When this multiproteic complex cannot be formed, due to gene 
mutations leading to the lack of cathepsin, both sialidase NEU1 and β-galactosidase are not 
active. In this case, a lysosomal storage disease called galactosialidosis occurs. Instead,  gene 
mutations leading to the deficiency of NEU1 sialidase are the bases of the lysosomal storage 
disorder called sialidosis. Both galactosialidosis and sialidosis are lethal within few 
months/years after the birth. NEU1 negatively regulates the lysosomal exocytosis, in 
haematopietic cells, by processing the sialic acid residues carried by the lysosomal 
membrane protein, Lamp-1. Increase in the lysosomal exocytosis is caused by the 
oversialylation of Lamp-1 whereas a decrease in the lysosomal exocytosis is due to the 
desialylation of Lamp-1 (Miyagi T, 2012). A recent study reported that the regulation of 
lysosomal exocytosis acted by NEU1 plays a significant role in tumor progression and 
chemoresistance (Machado E, 2015). 
Apart from  glycoconjugate catabolism in lysosomes, NEU1 is also involved in 
cellular signaling processes targeting β4 integrin. Low levels of sialylated β4 integrin due to 
NEU1 over-expression in human colon cancer cells induce the subsequent attenuation of 
FAK and ERK1/2 pathways and the down-regulation of the matrix metalloprotease 7, 
leading to the suppression of metastasis (Uemura T,  2009). Overall, in many tumors, NEU1 
has been shown to be down-regulated. 
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Biochemical subcellular fractionization and immunostaining evidences shows that 
NEU2 sialidase is located in the cytosol (Miyagi T, 2012). The tridimensional structure of 
NEU2 has been determined by X ray: NEU2 is composed by six-blade beta propeller and its 
active site is located in a shallow crevice, as observed in viral and bacterial sialidases 
(Chavas LM, 2005). NEU2 sialidase is involved in the muscle, neuronal and erythrocyte cell 
differentiation. It works towards a wide range of oligosaccharides, glycoproteins, and 
glycolipids at both acidic and neutral pH. NEU2 is not expressed in all tissues; its high 
expression is seen in the skeletal muscles. The downregulation of NEU2 gene was associated 
with the impairment of muscle regeneration and differentiation (Miyagi T, 2012). NEU2 
wasalso found to be involved in carcinogenesis. The high invasive and metastatic B16-BL6 
melanoma mouse cell line gave rise to a lower number of pulmonary metastases,  after 
NEU2 over-expression, due to a decreased content of ganglioside GM3 and an increased 
level of lactosylceramide (Miyagi T, 2012). Moreover, the over-expression of NEU2 in 
human leukemic cells, K562, decreased apoptosis resistance (Tringali C,  2007). 
 
Sialidase NEU3 is associated with the plasma membrane and is mainly located in lipid 
rafts. NEU3 can also move to membrane ruffles  together with Rac1 (Miyagi T, 2012) and in 
endososomes (Zanchetti G, 2007).  NEU3 has a strict substrate specificity toward 
gangliosides. It has been found NEU3 is upregulated in various human cancer and promotes 
malignant phenotype regulating several cell properties including migration, invasiveness, 
and survival (Miyagi T, 2012). Indeed, NEU3 participates in the skeletal muscle 
differentiation, in neuronal cell differentiation, and in adaptive immune response (Miyagi T, 
2012). Together NEU1 and NEU3 are upregulated during dentritic cell differentiation of 
monocytes (Miyagi T, 2012). 
 
Sialidase NEU4 is a membrane-bound enzyme and, in humans, it is present as two 
forms, long and short (NEU4L and NEU4S), differing for 12 aminoacids at the N-term. 
Liver and colon mainly express NEU4S; brain, muscle, and liver express both NEU4L and 
NEU4S. At a subcellular level, the long form of NEU4 localizes in mitochondria, while the 
short form is mainly associated with the endoplasmic reticulum. Both forms exhibit substrate 
specificity to oligosaccharides, glycoproteins, and glycolipids. In mouse, NEU4 is expressed 
predominantly in the brain, whereas it is found very low in other tissues. NEU4 plays a 
major role in brain development by digesting polysialic acids on the surfaces of neuronal 
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cells (Miyagi T, 2012). Moreover, the long form of human NEU4 is involved in the 
regulation of neuronal cell apoptosis (Hasegawa T, 2007). 
In contrast to NEU3, the human colon cancer cells showed decreased NEU4 mRNA 
levels (Miyagi T, 2012). 
 
Some properties of human sialidases are resumed in Tab.1. 
 
 Table 1: Human sialidase (Miyagi T, 2008). 
 
 NEU1 NEU2 NEU3 NEU4 
Major 
subcellular 
localization 
Lysosomes Cytosol 
Plasma 
membrane 
Lysosomes, 
Mitochondria, 
intracellular 
membrane 
Good 
substrates 
Oligosaccharides, 
Glycopeptides 
Oligosaccharides, 
Glycoproteins, 
Gangliosides 
Gangliosides 
Oligosaccharides, 
Glycoproteins, 
Gangliosides 
Optimal pH 4.4 - 4.6 6.0 - 6.5 4.6 - 4.8 4.4 - 4.5 
Total 
aminoacids 
    
(Human) 415 380 428 496 (484) 
(Mouse) 409 379 418 478 
Chromosome 
location 
    
(Human) 6p21.3 2q 37 11q13.5 2q37.3 
(Mouse) 17 1 7 10 
Frequent 
changes in 
cancer 
Down Down Up Down 
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2.2. GENE ORGANIZATION OF HUMAN SIALIDASES 
 
The human gene, NEU1, was identified in the chromosome 6p21.3, consists of six 
exons that span in about 5kb (Milner CM, 1997) (Fig. 4). NEU1 protein has 415 aminoacids 
and a molecular weight of 45.5kDa. The predicted aminoacid sequence has homology to the 
mammalian cytosolic sialidase and to bacterial sialidases, including the F(Y)RIP sequence, 
the Asp boxes and a potential N-linked glycosylation site (Miyagi T, 2012). 
 
The human gene, NEU2, is very short, has only two exons, and is located on 
chromosome 2q37.1 region (Figure 4). NEU2 protein consists of 380 aminoacids with a 
molecular weight of 42.8kDa (Monti E, 1999). The promoter region contains a classic 
TATA box and four E-boxes that are DNA binding motif recognized by several nuclear 
factors belonging to the basic helix-loop-helix family of DNA binding protein (Monti E, 
1999). Among other mammalian sialidases, NEU2 cDNA was first cloned (Miyagi T, 1993). 
 
The human gene, NEU3, comprises of four exons encompassing over 22kb, located in 
the chromosome region 11q13.5 (Fig. 4) (Monti E, 2000). The nucleotide sequence of NEU3 
in human, mouse and rat shows higher homology in the open reading frame and, in turn, 
exhibits higher identity in the aminoacid sequences. (Miyagi T, 2012). In humans, the 
deduced sequence of NEU3 comprises 428 aminoacids, that contains one F(Y)RIP-box and 
three Asp boxes in the N-terminal and in the center of the aminoacid sequence. Sequence 
analysis of the 58 untranslated regions reveals the presence of several Sp1-binding sites and 
the absence of TATA and CAAT box sequences, in agreement with the Northern blot 
analysis that shows a ubiquitous expression pattern. 
 
The human gene, NEU4, identified by searching sequence databases for entries 
showing homologies to the human cytosolic sialidase NEU2, maps in the telomeric region of 
the long arm of chromosome 2 (2q37.3), and is organized in four exons (Figure 4). The 
NEU4 gene encodes a 484-residue protein; the predicted NEU4 protein contains all the 
typical sialidase amino acid motifs and, apart from an amino acid stretch that appears unique 
among mammalian sialidases, shows high sequence homology with the cytosolic (NEU2) 
and the plasma membrane-associated (NEU3) enzymes. 
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Summing up, all the mammalian sialidases cloned so far show high degree of 
homology and share amino acid blocks of highly conserved residues, F(Y)RIP motif and 
Asp boxes in topologically equivalent positions throughout the primary structure (Monti E, 
2002). In addition, 8 or 9 of 12 of the amino acid residues that form the catalytic site of S. 
thypimurium enzyme are conserved (Crennell SJ, 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Structure of human NEU1, NEU2, NEU3 and NEU4 genes (Miyagi T, 2012). 
 
In 1993, the first mammalian sialidase was cloned: it was the rat cytosolic sialidase. Its 
first analysis demonstrated a significant homology with those of bacteria and virus: in 
particular, the domain F(Y)RIP at the ammino-terminus of the protein, and the so-called 
Asp-boxes (SxDxGxxT/W) (Roggentin P, 1989). The sequence F(Y)RIP is involved in the 
catalityc site of sialidases, giving an arginine that can interact with sialic acid carboxyl group 
during the stages of substrate binding and catalysis. Instead, it is believed that Asp boxes are 
involved in the folding of sialidases (Roggentin P, 1993). 
 
At the end of 1990s, the human lysosomal sialidase NEU1 was cloned and, in 1999, 
the human cytosolic sialidase NEU2 was also identified and cloned (Monti E, 1999); after 
one year, the sialidase NEU3 was discovered (Monti E, 2000). In 2004, NEU4 was identified 
(Monti E, 2004). 
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Overall, the level of similarity between sialidases from different species reaches 75%; 
for these reasons, it was hypothesized that a common ancestral gene could exist (Schauer R, 
1984). 
 
2.3. NEU3 SIALIDASE AND CANCER  
 
As previously outlined, several reports indicate that NEU3 is upregulated in various 
cancers including colon, renal, ovarian and prostate. In contrast, in acute lymphoblastic 
leukemia, NEU3 appeared to be down-regulated (Mandal C, 2010). Moreover, many 
evidences suggest that it can be responsible for the appearance of many alterations among 
sialoglycoconjugates in cancer cells (Miyagi T, 2012). Many data concur to classify NEU3 
as a novel oncogene (Yamaguchi K, 2006). 
 
In particular, in human colon cancer cells, NEU3 sialidase is 3 to 100 fold increased, 
as mRNA level, compared to non-tumor mucosa. Instead, during sodium butyrate-induced 
apoptosis, colon cancer cells showed to undergo to the down-regulation of NEU3 
expression. On the other hand, NEU3 gene transfection into colon cancer cells inhibited 
sodium butyrate-induced apoptosis, by increasing the expresssion of the anti-apoptotic 
protein, Bcl2. It has been suggested that lactosylceramide, a product of NEU3 action on 
cellular gangliosides, could be responsible for the anti-apoptotic and pro-survival effects 
elicited by NEU3 over-expression. 
 
Moreover, in colon cancer cells, NEU3 regulates cell proliferation modulating the 
integrin mediated signaling triggered by adhesion to the proteins constituting the 
extracellular matrix, in particular laminin. Triggered by laminin, NEU3 enhanced tyrosine 
phosphorylation of integrin β4 together with the recruitment of Shc and Grb-2 and the 
stimulation of FAK and ERK1/2 phosphorylation (Miyagi T, 2012). 
 
In colon cancer cells, the silencing of NEU3 induced the down-regulation of the Wnt 
pathway (Wnt1, Wnt3a and EGFR) (Takahashi K, 2015). 
 
Also, in renal carcinoma cells, NEU3 has been demonstrated to be up-regulated. Here, 
NEU3 up-regulation was closely interconnected with IL-6 signalling. NEU3 enhanced IL-6 
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signalling promoting the PI3K/AKT signaling pathway and thus contributing to suppression 
of apoptosis and migration (Miyagi T, 2012). Downregulation of NEU3 decreased AKT 
phosphorylation and inhibited Rho activation (Ueno S, 2006).  
 
In renal carcinoma CA-TC cells, NEU3 silencing increased the content of ganglioside 
GD1a leading to the up-regulation of RAB25 and to the downregulation of the chloride 
intracellular protein 3 (CLIC3). These events strongly affected the trafficking and recycling 
of β1 integrin to the plasma membrane leading to a higher degradation and to a minor 
content of  β1 integrin at the plasma membrane (Tringali C, 2012).  
 
Upregulation of NEU3 is also detected in prostate cancer. In the prostate cancer cell 
line, PC-3, the silencing of NEU3 caused a reduction in cell growth both in vitro and in vivo 
and the decrease of cell migration and invasion. The studies suggested the role of NEU3 in 
the progression of prostate cancer through androgen receptor signaling (Miyagi T, 2012). 
 
In chronic myeloid leukemia cells, K562, NEU3 silencing reduced proliferation rate 
and apoptosis resistance, triggering megakaryocitic differentiation (Tringali C, 2009). 
 
Many effects above described and triggered by the up-regulation of NEU3 are caused 
by the modulation acted by this sialidase on signalling molecules, such as the epidermal 
growth factor receptor (EGFR), FAK, ILK, and integrins. Regarding EGFR, many studies 
indicated a link between NEU3 and the activation of EGFR downstream pathways. It was 
shown that human sialidase NEU3 co-immunoprecipitate with EGFR and can modulate its 
activation modifying the sorrounding gangliosides or the level of sialylation of EGFR itself 
(Mozzi A, 2015). Moreover, EGF is able to stimulate NEU3 activating the phospholipase D 
(PLD1) and the formation of phosphatidic acid. Phosphatidic acid was demonstrated to be a 
strong inducer of NEU3 translocation to the plasma membrane (Shiozaki K, 2016). 
 
NEU3 has been demonstrated to be over-expressed also in melanoma. NEU3 silencing 
in the melanoma cell line MeWo reduced cell growth similarly to that observed in other 
tumours (Miyata M, 2011). 
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All these data demonstrated that the NEU3 plays a key role in tumorigenesis and that it 
could be involved also in melanoma development. These evidences constitute the basis of 
the present thesis. 
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3. AIMS OF THE THESIS 
 
Among many other alterations regarding oncogenes, tumour suppressors and signalling 
pathways, melanoma cells have been demonstrated to be characterized also by the up-
regulation of the plasma membrane sialidase NEU3 (Miyata M, 2011; Tringali C, 2014). 
 
Sialidase NEU3 is also known as the “ganglioside sialidase” due to its strict substrate 
preference. As discussed in the Introduction paragraph, melanoma cells are marked by the 
presence of atypical gangliosides, not usually present in normal melanocytes. This evidence 
induced also the employment of anti-ganglioside vaccines. Moreover, it has been 
demonstrated that gangliosides can significantly influence the aggressiveness of melanoma 
cells. Thus, it can be hypothesized that NEU3 alterations could be involved in the 
modulation of melanoma cell ganglioside profile and, therefore, in its malignancy. 
 
A previous paper demonstrated that NEU3 silencing/over-expression modified 
melanoma cell survival capability (Miyata M, 2011). Moreover, preliminary results obtained 
in my laboratory demonstrated that NEU3 silencing significantly reduced the growth of 
primary melanoma cells in soft agar and in vivo, along to their migration potential. Genome-
wide expression profiling and GO enrichment analysis demonstrated that many genes altered 
by NEU3 silencing are related to the control of migration, differentiation, and survival. 
 
Therefore, based on these data, the aims of this thesis were: 
- to validate by Real Time PCR the expression of genes emerged by microarray analysis 
and related to the control of migration and motility; 
- to analyse the expression as proteins of markers of epithelial-mesenchymal transition, 
as this process is related to both differentiation and altered adhesion and motility, in 
melanoma cells; 
- to identify the signalling pathways changed by NEU3 silencing and possibly related to 
the control of epithelial-mesenchymal transition and motility. 
 
To pursue this aims, two primary melanoma cell lines, named L3 and L6, and previously 
established NEU3 silenced clones were employed. 
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4. MATERIALS AND METHODS 
 
4.1. CELL CULTURE 
 
Primary human melanoma called 3 and 6 and established by Fondazione IRCCS 
Istituto Nazionale dei Tumori at Milan were grown at 37°C, in the presence of 5% CO2. 
Cells were grown in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum 
(FBS), 1% glutamine and 1% pencillin, and streptomycin. Cells were cryopreserved in a 
medium constituted by 90% FBS and 10% DMSO, in liquid nitrogen. 
 
Stable NEU3 silenced cloned were previously obtained through a lenti-viral approach, 
in the laboratory where I worked for this thesis: for melanoma cell line 3, NEU3 silenced 
clone 3C was obtained; for melanoma cell line 6, NEU3 silenced clones 6A and 6B were 
obtained. 
 
4.2. CELL LYSIS 
 
7.5 x 105 mock and NEU3 silenced cells from cell line 3 and 6.5 x 105 mock and 
NEU3 silenced cells from cell line 6 were usually plated in 100 mm plates and cultivated for 
48 hours, at 37°C. Then, cells were harvested by scraping and by centrifugation (300xg, 5 
minutes, 4°C). Cell pellets were resuspended using phosphate buffered saline (PBS) (137 
mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4) and adding EDTA 
free protease inhibitor cocktail and 1 mM sodium orthovanadate (Roche). Then, cells were 
homogenized by sonication (2 pulses, 10 sec). Total cell lysate were employed for Western 
blot analysis. 
 
For sialidase activity assay, total cell lysates were centrifuged at 800×g, for 10 
minutes, at 4°C to remove unbroken cells and nuclei from the crude homogenate. 
Subsequently, the crude homogenates were again centrifuged at 70,000 x g, for 20 minutes, 
at 4°C to separate cellular membranes from cytosol. The pellets containing plasma 
membranes were resuspended in PBS with protease inhibitors and 1 mM sodium 
orthovanadate. 
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4.3. BRADFORD PROTEIN ASSAY 
 
The protein assay was performed using Bradford method. The concentration of 
proteins in samples was measured by comparing it with standard calibration curve prepared 
using bovine serum albumin (BSA) at three concentrations (1 µg/ml, 2 µg/ml, 3 µg/ml). 
Coomassie blue diluted in water with 1:4 ratio and 1 ml of this solution was added to 
samples and blank containing only water. Absorbance was measured at 595 nm using 
JASCO spectrophotometer.  
 
4.4. SIALIDASE ACTIVITY ASSAY 
 
Sialidase activity present in mock and NEU3 silenced clones obtained from melanoma 
cell lines 3 and 6 was assayed by using the artificial fluorescent substrate 4-
methylumbelliferyl-N-acetyl-D-neuraminic acid (MU-NeuAc) and membranes prepared as 
described in paragraph 4.2.  
 
A reaction mixture was prepared as follows: 
Ø Membrane preparations - 10µg 
Ø Bovine serum albumin (BSA) - 600µg 
Ø MU-NeuAc - 0.1mM (10µl) 
Ø Phosphate/Citrate buffer - 0.5M, pH 3.8 (10µl) 
Ø Standard MU-Na - 0.5nM 
Distilled water was added to make the total volume 100µl. 
 
The samples were incubated in water bath at 37°C, for 30 minutes and subsequently, 
0.2M glycine pH 10.8 was added to the samples and enzyme reaction was stopped. 
 
0.5 mole standard MU-Na (methylumbelliferone-Na) was added in a total volume of 
100 µl, in water. The fluorescence was measured at excitation λ of 365 and emission λ of 
448, using the Nanodrop 3300 fluorospectrometer, 4MU program set up. Glycine was used 
as blank. 
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The enzyme activity was expressed as U/mg protein: U equals to 1µmole substrate 
released in 1 minute. 
 
4.5. SDS-PAGE 
 
The discontinuous polyacrylamide gel electrophoresis was used to separate the 
proteins.  
 
20-30 µg of cell lysate were diluted with sample buffer (62.5 mM Tris/HCl pH 6.8, 2% 
SDS, 10% Glycerol, 5% 2-mercaptoethanol, 0.01% Bromophenol blue), and boiled for 5 
minutes, at 100°C. Samples were loaded onto SDS-PAGE gel and electrophoresis was 
performed in Tris/glycine running buffer (25 mM Tris, 19.5 mM Glycine, 0.1% SDS, pH 
8.3), at 20-30 mA constant. 
 
The gel was constituted by a Running gel and a Stacking gel. 
 
Running Gel Composition (10% Acrylamide) 
Ø 1.5 mM Tris/HCl, pH 8.8 
Ø 10-12% Acrylamide 
Ø 0.1% w/v SDS 
Ø 0.05% w/v ammonium persulphate (APS) 
Ø TEMED 
Ø H2O 
 
Stacking Gel Composition (4% Acrylamide) 
Ø 0.5 mM Tris/HCl, pH 6.8 
Ø 4% Acrylamide 
Ø 0.1% w/v SDS 
Ø 0.05% w/v ammonium persulphate (APS) 
Ø TEMED 
Ø H2O 
 
After the running, proteins were transferred onto PVDF membrane for western blot analysis. 
	 23	
4.6. WESTERN BLOT 
 
Proteins were transferred onto PVDF membrane (25 mM Tris, 190 mM glycine, pH 
8.3 plus 20% methanol), at 100V, for 2 hours, at 4°C. The membrane was incubated with 
blocking buffer for 1 hour in shaker at room temperature in order to saturate nonspecific 
binding of antibodies. The blocking buffer was constituted by 5% non-fat milk powder in 
TBS (50 mM Tris/HCl, 0.15 M NaCl, pH 7.4) plus 0.1% (w/v) Tween 20. After blocking, 
the membrane was washed 3 times for 5 minutes, in TBS-Tween 20 (wash buffer). 
Followed, the primary antibodies diluted in blocking buffer were added onto the membrane 
and incubated overnight, at 4°C.  
 
After incubated with primary antibody (Tab.2), membrane was washed with wash 
buffer (TBS-Tween 20) 3 times for 5 minutes. Subsequently, the peroxidase conjugated 
secondary antibody diluted in blocking buffer was added to the membrane and incubated in 
shaker for 45 minutes, at room temperature. After that, the membrane was washed 3 times 
with TBS-Tween 20 for 5 minutes. The Chemiluminescent substrate (Bio-Rad and Westar 
ηc ultra2 Pico/Dura Kit) was added to the membrane and incubated under dark condition for 
5 minutes. The membrane was placed in UVITEC; image was captured and quantitative 
protein expression was analysed. 
 
Table 2: Antibodies used for western blot. 
 
Antibody Host Company 
N-Cadherin Rabbit Santa Cruz Biotechnology 
E-Cadherin Rabbit Cell Signaling 
Vimentin Rabbit Cell Signaling 
ZO-1 Rabbit Cell Signaling 
MITF Rabbit Sigma Aldrich 
Claudin1 Rabbit Cell Signaling 
β-Actin Mouse Cell Signaling 
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4.7. STRIPPING OF MEMBRANES 	
After detecting the phosphorylated form of some proteins, the membranes were 
stripped to detect total proteins. To this end, membranes were put in stripping buffer (50 mM 
Tris/HCl pH 6.8, 2% SDS, 100 mM β-mercaptoethanol) for 20 minutes, at 50°C in water 
bath. 
 
After stripping, the membranes were washed using wash buffer (TBS-Tween 20) in 
order to eliminate β-mercaptoethanol for proper binding of antibodies to the target protein. 
After washing, the membranes were blocked with 5% milk in TBS-Tween 20 for 1 hour and 
then treated again with the primary antibody. 
 
4.8. PROTEIN ARRAY 
 
The PathScan®Intracellular signaling array kit (Chemiluminescent readout) (Cell 
Signaling) is a slide based antibody array used to detect several cellular proteins and 
signaling nodes only when phosphorylated or cleaved at the specified residues (ERK 1/2, 
Stat1, Stat3, AKT, AMPK alpha, S6 ribosomal protein, mTOR, HSP27, BAD, p70 kinase, 
PRAS40, p53, p38, SAPK/JNK, PARP, Caspase-3, GSK-3 beta). 
 
7.5 x 105 mock and NEU3 silenced cells from cell line 3 and 6.5 x 105 mock and 
NEU3 silenced cells from cell line 6 were plated in 100 mm plates and cultivated for 48 
hours. After, the medium was aspirated. The cell plates were kept on ice tray under cold 
condition. 4 ml of cold 1X PBS was added to the plates and aspirated immediately. 500 µl of 
lysis buffer (20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM disodium EDTA, 1 mM EGTA, 
1% Triton X-100, 20 mM sodium pyrophosphate, 25 mM sodium fluoride, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) containing EDTA free protease 
cocktail inhibitor was added to the cells and incubated on ice for 2 minutes. Then, cells were 
harvested by scraping, transferred into the eppendorf tubes and centrifuged for 2 minutes, at 
14.000xg, at 4°C. The supernatants containing cell lysates were collected. 
 
The protein assay was performed using Bradford method as described in paragraph 4.3 
with minor modifications. Because Triton X-100 interferes with this assay at high 
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concentrations, it was added to blank and to the standard calibration curve, at the same 
concentration present in samples.  
 
Cell lysates were diluted to reach a final concentration of 0.3 mg/ml and 0.6 mg/ml 
from total protein samples by using the array diluent buffer provided by the kit. 
 
Then, the procedure described by manufacturer was followed. In details, the glass slide 
was placed carefully on top of the multiwell gasket with the nitrocellulose pads facing down. 
The metal clips were inserted on both sides into the groove in the gasket and ensured that the 
clips were on the same side as the orientation line on the slide followed by rotating the clips 
into the locked position, assembled array is done. 
 
100 µl of the array-blocking buffer (provided by the manufacturer) was added to all the 
wells of the multiwell signaling array glass slide. Then it was covered with sealing tape, kept 
in shaker for 15 minutes. After discarding the blocking buffer from each well completely, 75 
µl of the diluted protein samples were added to their corresponding well and covered. 
Incubation was carried out overnight in shaker at 4°C. After incubation, the contents were 
discarded and washed with 150 µl of the array wash buffer 4 times for every 5 minutes. 
After washing, 75 µl of 1X detection antibody cocktail (provided by the manufacturer) was 
added to each well. The array was covered by sealing tap and incubated for 1 hour in shaker. 
After incubation, the wells were washed with 100 µl of 1X array wash buffer for 4 times 
with each duration of 5 minutes. Followed, 75µl of 1X HRP-streptovidin (secondary 
antibody) was added to wells and incubated in shaker for 30 minutes. After incubation, the 
wells were washed 4 times for every 5 minutes with 100 µl of 1X array wash buffer. The 
glass slide was removed from the gasket and put inside the box filled with 10 ml of 1X array 
wash buffer and washed briefly. After decanting array wash buffer, the glass slide was 
covered with 10 ml of LumiGLO® and peroxide chemiluminescent reagents. The glass slide 
was transferred into UVITEC and images were captured by detecting chemiluminescent 
signals immediately. Spot intensity was quantified by using array image analysis software. 
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4.9. RNA EXTRACTION 
 
Total RNA was extracted from 7.5 x 105 mock and NEU3 silenced cells from cell line 
3 and from 6.5 x 105 mock and NEU3 silenced cells from cell line 6 cultivated for 48 hours, 
at 37°C, using RNeasy mini kit (Qiagen). Plated cells were detached by using trypsin. Cell 
pellets were obtained by centrifuging at 300xg, for 5 minutes. The cell pellets were lysed by 
adding 350 µl RLT buffer (cell lysis buffer). Followed, 350 µl of 70% ethanol mix was 
added, vortex and finally transferred into the column filter. Centrifugation was done at 
8000×g for 30 seconds and supernatant was removed. 350 µl of RW1 (wash buffer) was 
added to the column filter and again centrifuged at 8000×g for 30 seconds, supernatant was 
removed. In order to remove DNases contamination, 70 µl of digest buffer and 10 µl of 
DNases were mixed together in a separate tube and added into the column filter, incubated 
for 20 minutes in room temperature. Soon after, 350 µl of RW1 (wash buffer) buffer was 
added to column filter and incubated for 5 minutes, at room temperature. Centrifugation was 
done at 8000×g for 30 seconds and supernatant was removed. Followed, 500 µl RPE  (wash 
buffer) was added and centrifuged at 8000×g for 30 seconds. After the removal of 
supernatants, again 500 µl RPE (wash buffer) was added and centrifuged at 8000×g for 2 
minutes. The column filter was transferred into another eppendorf tube in order to dry the 
filter completely, centrifuged to the maximum speed for 30 seconds. 40 µl of RNase free 
water was added to the column filter and incubated for 1 minute at room temperature, and 
centrifuged at 8000×g for 1 minute. In this way, the total RNA was isolated. 
 
4.10. RNA CONCENTRATION ASSAY 
 
The RNA assay was done by using Ribogreen RNA reagent (Life Technologies), 
which is one of the most sensitive detection dye for analysing linear fluorescence for the 
quantitation of RNA. The Ribogreen reagent bound to RNA has a maximum absorbance at 
500 nm and a maximum emission at 525 nm. A standard calibration curve with a mixture of 
rRNA (16S and 23S) was prepared, at four concentrations. The Ribogreen was diluted 1:200 
in TE buffer (200 mM Tris-HCl, 20 mM EDTA, pH 7.5). 100 µl of aqueous Ribogreen was 
added to the RNA samples and to standards and incubated at room temperature, for 5 
minutes.  
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Fluorescence was detected by using Nanodrop 3300 fluorospectrometer at the above 
reported wavelengths. 
 
4.11. REVERSE - TRANSCRIPTION OF RNA 
 
Quantitative gene expression was carried out through the creation of complementary 
DNA (cDNA, transcripts from RNA) using reverse transcriptase enzyme. 
 
The reverse transcription process was carried out by using 800 ng from total RNA 
using the iScript cDNA synthesis kit (Bio-Rad Laboratories). 
 
Reaction mix was made as follows: 
 
Ø 4 µl of 5X iScript reaction mix (containing oligo (dT) and random hexamer primers) 
Ø 1 µl of iScript reverse transcriptase 
Ø 800 ng of RNA 
 
Nuclease free water was added to make the final volume to 20 µl. 
 
The complete reaction mix was incubated in a thermal cycler (Eppendorf) using the 
following protocol: 
 
Annealing - 5 minutes at 25°C 
Reverse transcription - 25 minutes at 42°C 
Reverse transcriptase inactivation - 5 minutes at 85°C 
Hold at 4°C 
 
A negative control containing only RNA and water was prepared to verify the absence 
of genomic DNA contamination. 
 
4.12. REAL TIME PCR 
 
Real Time PCR was performed using the fluorescent dye SYBR green. 
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The reaction mix contained: 
Ø 15-25 ng cDNA; 
Ø 200 nM primers (reported in Table 3); 
Ø 10 µl of SYBR Green super mix  (Bio-Rad Laboratories) containing hot-start 
iTaq DNa Polymerase, dNTPs, SYBR Green I, fluorescein and ROX 
normalization dye. 
 
Distilled water was added to make the final volume 20µl. 
To check a possible contamination in the reaction, blanks were prepared without cDNA. 
 
By using iCycler Bio-Rad, we followed this protocol: 
 
Denaturation - 95°C for 1 minute and 30 seconds 
 
Denaturation - 95°C for 10 seconds 
Annealing     repeat 45 cycles  
Extension - 58°C for 30 seconds 
Detection of Fluorescence 
 
After amplification process, melting-curve analysis was done to exclude the presence 
of non-specific products. 
 
Data were analysed using the software distributed by the manufacturer (Bio-Rad 
Laboratories). 
 
 
Table 3: Primers used for REAL -TIME PCR. 
Gene Forward Reverse 
SEMA 3B 5’-AGGACATTGGTACTGAGTG-3’ 5’-CATCCTCTATCCTTCCTGG-3’ 
SEMA 3C 5’-ATCAATGAGGAGCTTTTCTC-3’ 5’-TTCCTCTTGGTTAAACTTCG-3’ 
SEMA 5A 5’-CTATAAAGAAATTGGCCCCTG-3’ 5’-ACAACAAGTTCTTTCTGTCC-3’ 
NEU3 5’-GGCTTGTTTGGGTGTTTGTT-3’ 5’-TTTTGAATTGGCTTGGGTTC-3’ 
β -ACTIN 5’-CGACAGGATGCAGAAGGAG-3’ 5’-ACATCTGCTCCAAGGTGGA-3’ 
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5. RESULTS 
 
5.1. NEU3 SIALIDASE mRNA EXPRESSION AND ACTIVITY IN NEU3 
SILENCED CLONES ESTABLISHED FROM PRIMARY MELANOMA 
CELL LINES 
 
In order to understand the role of NEU3 in melanoma malignancy, NEU3 was stably 
silenced employing a lentiviral approach, in two primary melanoma cell lines named, L3 and 
L6. These cell lines are characterized by a similar cellular ganglioside profile composed by 
GM3 and GD3 but are quite different regarding some biological features; in particular, cell 
line L3 retains the capability to produce melanin on the contrary of cell line L6. 
 
NEU3 silencing was verified in terms of both NEU3 mRNA expression (by Real Time 
PCR) and membrane sialidase activity (toward 4-MUNeuAc). 
 
We recorded the decrease of NEU3 mRNA expression in clone 3C compared to L3 
mock cells (-35%) (Fig. 5A) and in clone 6A (-30%) (Fig. 5A), and in clone 6B (-31%) (Fig. 
5A) compared to L6 mock cells. 
 
In parallel, we recorded the decrease of membrane sialidase activity in clone 3C 
compared to L3 mock (-29.15%) (Fig. 5B), and in clone 6A (-10.25%) (Fig. 5B) and in clone 
6B (-39.40%) (Fig. 5B) compared to L6 mock cells. It should be noted that membrane 
sialidase activity consists of both NEU1 and NEU3 activity; NEU1 expression did not 
change among the clones belonging to both L3 and L6 cell lines. 
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Figure 5: (A) Expression of NEU3 gene assessed by Real Time PCR. (B) Membrane 
sialidase activity toward 4MU-NeuAc, in mock L3 and its NEU3 silenced clone iNeu3 3C, 
and in mock L6 and its NEU3 silenced clones, iNeu3 6A and iNeu3 6B. Significance was 
calculated by unpaired t-Student test. *: P<0.05; **: P<0.01; ***: P<0.001. 
 
5.2. THE EXPRESSION OF SOME GENES INVOLVED IN 
MELANOMA MALIGNANCY ARE ALTERED BY NEU3 SILENCING 
 
Microarray analyses performed in the laboratory where I worked for PhD revealed that 
NEU3 silencing altered the expression of some genes related to cell motility and cell 
survival. 
We validated some results by Real Time PCR. 
 
In particular, we confirmed that the gene MAL was up-regulated in both NEU3 
silenced clones of cell line 3 (11.6 - fold) and cell line 6 (148 - fold in clone 6A and 21 - fold 
in clone 6B) (Fig. 6A). MAL encodes an integral protein, which plays a key role in the 
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formation and maintenance of glycosphingolipid membrane domains (Magal LG, 2009). It is 
significantly down-regulated in many epithelial tumours (Mimori K, 2003; Cao W, 2010). 
 
The expression of the semaphorin 3B (SEMA 3B) was up-regulated in both NEU3 
silenced clones of cell line 3 (0.53 - fold) and cell line 6 (2.63 - fold in clone 6A and 1.93 - 
fold in clone 6B) (Fig. 6B). Semaphorin 3B is an angiogenesis inhibitor (Varshavsky A, 
2008) and inhibits the PI3K-AKT pathway in breast and lung tumours (Castro-Riviera E, 
2008). It is known as tumour suppressor (Capparuccia L, 2009). 
 
Semaphorin 3C (SEMA 3C) was up-regulated only in silenced clones of cell line 6 (4 - 
fold in clone 6A and 1.3 - fold in clone 6B) (Fig. 6C). SEMA 3C has oncogenic effects in 
some cancers but it is also an inhibitor of tumour lymphangiogenesis and metastasis 
(Mumblat Y, 2015). 
 
Semaphorin 5A (SEMA 5A) was down-regulated in both NEU3 silenced clones of cell 
line 3 (-0.47 - fold) and cell line 6 (-0.37 - fold in clone 6B) (Fig. 6D). SEMA 5A 
demonstrated oncogenic effects in gastric and pancreatic cancers  (Lu TP, 2012). 
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Figure 6: Real time PCR analyses of MAL (A), SEMA 3B (B), SEMA 3C (C), and 
SEMA 5A (D). Significance was calculated by unpaired t-Student test. *: P<0.05; **: 
P<0.01; ***: P<0.001. 
 
5.3. THE EXPRESSION OF SOME PROTEIN RELATED TO 
EPITHELIAL-MESENCHYMAL TRANSITION ARE ALTERED BY 
NEU3 SILENCING 
 
Epithelial-mesenchymal transition (EMT) is a significant process responsible for the 
switching of cellular phenotype toward an invasive behaviour, in many tumours (Larue L, 
2005). During this event, epithelial cells acquire a mesenchymal behaviour, increasing their 
motility and altering adhesion properties (Larue L, 2005). It has been demonstrated that 
EMT occurs also in melanoma even if, in this case, it is more correct to define the process a 
pseudo-EMT. Many markers identified for EMT in carcinomas were detected also in 
melanoma cell lines, whereas others are typical of melanomas (Kim JE, 2013). 
 
We recorded the following changes (Fig. 7): 
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- N cadherin expression decreased in clone 6A (-0.7 - fold) and in clone 6B (-0.32 - 
fold), compared to mock L6 cells. No significant changes have been detected in clone 3C 
compared to mock L3 cells; 
 
- E cadherin expression increased in clone 3C compared to mock L3 cells (+1.81 - 
fold); E cadherin was not expressed by mock and NEU3 silenced L6 cells; 
 
- Vimentin expression decreased in clone 6A (-0.48 - fold) and in clone 6B (-0.29 - 
fold), compared to mock L6 cells. The decrease of vimentin expression was not statistically 
significant in clone 3C compared to mock L3 cells, but we recorded its tendency toward the 
reduction; 
 
- Zo 1 expression increased in clone 6B (+0.38 - fold) compared to mock L6 cells; 
 
- MITF expression increased in clone 6A (+0.52 - fold) and in clone 6B (+0.71 - fold), 
compared to mock L6 cells. No significant changes have been detected in clone 3C 
compared to mock L3 cells; 
 
- Claudin 1 expression increased in clone 3C compared to mock L3 cells (+0.25 - 
fold), in clone 6A (+0.27 - fold) and in clone 6B (+1.13 - fold), compared to mock L6 cells. 
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Figure 7: Western blot analysis of N, E cadherins, vimentin, Zo-1, MITF, and claudin 1 in 
mock L3, iNeu3 3C clone, mock L6, iNeu3 6A and 6B clones. Beta actin was employed 
as loading control.  
 
5.4. ANALYSIS OF SIGNALING PATHWAYS BY PROTEIN ARRAY 
 
As described in Material and Methods, in order to identify the signalling pathways 
altered by NEU3 silencing, we employed a protein array. 
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Thus, we revealed that, in both melanoma cell line 3 and 6, the substrates of the PI3K-
AKT pathway (mTOR, BAD, PRAS40) and p38 kinase were less phosphorylated, thus 
active in NEU3 silenced clones than mock cells (Fig. 8). 
 
 
Figure 8: Protein array 
 
 
 
 
 
 
 
 
 
Figure 8: Protein Array 
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6. DISCUSSION 
 
Aberrant glycosylation is a peculiar feature of cancer, reflecting specific changes in 
glycan biosynthesis and catabolism pathways (Meany DL, 2011). Alterations concerning the 
expression/functionality of several enzymes including glycosyltransferases and sialidases 
allow cancer cells to produce glycolipids and glycoproteins bearing modified glycan chains. 
These changes have been demonstrated to be largely functional to the malignant phenotype 
with particular reference to metastasis potential and invasiveness (Hakomori S, 2002). In this 
context, also modifications concerning the quantitative and qualitative expression of 
gangliosides play a key role. The type of gangliosides present on the plasma membrane can 
modulate key cellular processes including cell adhesion, proliferation, differentiation and 
oncogenic transformation. Therefore, in this view, both the synthesis and the catabolism 
pathways leading to ganglioside expression constitute fields of interest in cancer biology 
research.  
 
Ganglioside catabolism can occur directly on the plasma membrane due to the plasma 
membrane sialidase NEU3. NEU3 was first cloned from bovine brain and it is also known as 
the “ganglioside sialidase” due to its strict substrate specificity (Miyagi T, 2012). NEU3 is 
markedly up-regulated in various human cancers, including colon, renal, ovarian and 
prostate and this event contributes to augmentation of malignant properties of cancer cells by 
causing disturbance of transmembrane signaling (Miyagi T, 2012). In particular, it has been 
demonstrated the involvement of NEU3 in association with gangliosides in processes such as 
adhesion, differentiation, proliferation, and apoptosis resistance (Rodriquez Walker M, 
2015).  
 
Melanoma cells summarize all these features, being characterized by an altered 
expression of gangliosides and the up-regulation of NEU3 (Miyata M, 2011; Tringali C, 
2014). Previous results collected in my laboratory but not still published demonstrated that 
NEU3 silencing in primary melanoma cell lines established from patients reduced cell 
growth in soft agar and in vivo and migration. 
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Starting from these data, this research project was aimed to understand the role of 
NEU3 in melanoma malignancy, focusing on signaling pathways involved in the control of 
cell motility and differentiation.  
 
Two different primary human melanoma cell lines were used in this study: they were 
characterized by similar cellular ganglioside profiles enriched by GM3 and GD3 and were 
established from patients with short survival. Nevertheless, they also were endowed with 
some different biological properties.  In particular, cell line L3 had the capacity to produce 
melanin contrary to cell line L6.  
 
A lentiviral approach was used to produce stable silencing of NEU3. NEU3 silencing 
was verified by assaying NEU3 mRNA expression by Real Time PCR and membrane 
sialidase activity towards 4-MUNeuAc.  
 
We first identified a different expression of some genes related to cell motility in 
NEU3 silenced melanoma cells. In particular, MAL has been demonstrated to be deeply up-
regulated in both NEU3 silenced clones established from cell line 3 and 6. Interestingly we 
observed a 148-fold increase in clone 6A of cell line L6 (Fig. 6A). Even if, MAL is also 
known as the T-cell differentiation protein, it is expressed also by other cell types and its 
down-regulation has been described in various epithelial malignancies (Cao W, 2010). MAL 
over-expression in esophageal cancer has been demonstrated to reduce migration in addition 
to modifying other properties (Mimori K, 2003). 
 
Moreover, we recorded a different expression of some semaphorins. Semaphorins are 
proteins, which participate in many physiological and developmental functions. The 
semaphorin family includes more than 30 genes, which are divided into seven subfamilies, 
characterized by the presence of the SEMA domain (Neufeld G, 2016). The members of  the 
SEMA family are differentially expressed in cancer and either promote or suppress cell 
proliferation, migration, angiogenesis and induction of drug resistance. Selected members of 
the semaphorin 3 family are involved in the suppression of tumor progression and are 
considered as potent tumor suppressors. SEMA3s are secreted by cells of multiple lineages, 
including epithelial cells, neurons, and specific tumor cells (Loginov VI, 2015). 
Significantly, we demonstrated that both NEU3 silenced clones of cell line L3 and cell line 
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L6 up-regulated semaphorin 3B  (Fig. 6B). Instead,, the expression of semaphorin 3C was 
up-regulated only in NEU3 silenced clones of cell line L6 (Fig. 6C). 
 
Semaphorin 5A seems to act as an oncogene in some tumors, i.e. gastric and pancreatic 
cancers (Lu TP, 2012). Its expression was down regulated in both NEU3 silenced clones of 
cell lines 3 and 6 (Fig. 6D).  
 
In addition to these results, we recorded in NEU3 silenced clones a different 
expression of some markers of EMT. EMT is a process by which cells loose epithelial 
characteristicd and gain a migratory mesenchymal phenotype (Gonzalez DM, 2014). we 
observed a decreased N-Cadherin expression in NEU3 silenced clones established from cell 
line 6, whereas increased expression of E-Cadherin was observed in clone 3C of cell line 3. 
 
The mesenchymal marker vimentin decreased in clone 6A and 6B of cell line 6 when 
compared to mock cells; instead, no significant decrease of vimentin was observed in mock 
NEU3 silenced clone 3C (Fig. 7). 
 
We also recorded an increased expression of ZO-1 and claudin 1 after NEU3 silencing 
further demonstrating changed cell-cell interactions and the increased expression of MITF. 
 
MITF is a master regulator of melanocyte differentiation and stimulates melanin 
synthesis and acts as a marker of EMT in melanoma, decreasing during the acquisition of the 
mesenchymal phenotype. The increased expression revealed in NEU3 silenced clones 
demonstrated that a partial differentiation process occurred. 
 
Summing up, these results prove the acquisition of a different molecular phenotype 
after NEU3 silencing that could explain the less motile properties of these cells. 
 
Based on our results, the signalling pathway involved in these changes appeared to be 
the PI3K/AKT. In fact, we revealed that PRAS40, a substrate of AKT, mainly AKT3 
(Madhunapantula SV, 2007) was less phosphorylated in NEU3 silenced clones. 
Significantly, PI3K/AKT is also involved in EMT induction (Xu W, 2015). 
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Thus, our results demonstrated that NEU3 silencing could reduce the 
PI3/AKT/PRAS40 signalling pathway and thus induce a less aggressive cell phenotype.  
 
Therefore, NEU3 could constitute a novel target in melanoma. 
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